Rabbit Recombinant Monoclonal eNOS phospho S1177 antibody. Carrier free. Suitable for IP, Dot, WB and reacts with Human, Mouse, Synthetic peptide samples. Cited in 4 publications.
pH: 7.2 - 7.4
Constituents: PBS
IP | Dot | WB | |
---|---|---|---|
Human | Tested | Expected | Tested |
Mouse | Expected | Expected | Tested |
Synthetic peptide | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Select an associated product type
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway (PubMed:1378832). NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C. Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.
Nitric oxide synthase 3, Constitutive NOS, EC-NOS, NOS type III, cNOS, NOSIII, Endothelial NOS, eNOS, NOS3
Rabbit Recombinant Monoclonal eNOS phospho S1177 antibody. Carrier free. Suitable for IP, Dot, WB and reacts with Human, Mouse, Synthetic peptide samples. Cited in 4 publications.
pH: 7.2 - 7.4
Constituents: PBS
ab230158 is the carrier-free version of Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
ENOS also known as endothelial nitric oxide synthase is an enzyme important for the production of nitric oxide (NO) in blood vessels. This protein with a molecular weight of approximately 133 kDa is expressed mostly in endothelial cells. eNOS plays a mechanical role in synthesizing NO from L-arginine a process requiring cofactors such as NADPH and oxygen. The activity of eNOS can be investigated through techniques such as Western blot with specific assays like phospho-eNOS ELISA available to measure its phosphorylated forms indicating activated states of the enzyme.
ENOS contributes significantly to the regulation of vascular tone and blood flow by promoting vasodilation. It does not function alone; instead it forms complexes with other proteins to exert its full effect. eNOS activity influences the process of angiogenesis inflammation modulation and platelet aggregation. Through its ability to produce nitric oxide eNOS acts as a signaling molecule helping maintain vascular homeostasis.
ENOS is a critical player in the NO signaling pathway and interacts intricately with the PI3K/Akt pathway. Nitric oxide produced by eNOS has a role in signaling cascades that lead to vascular dilation and reduced blood pressure. The PI3K/Akt pathway regulates eNOS activity via phosphorylation enhancing NO production. Other proteins like caveolin-1 and calmodulin modulate eNOS impacting these pathways' outcomes.
ENOS is associated with cardiovascular conditions like atherosclerosis and hypertension. Dysfunction of eNOS can lead to reduced NO production impairing vasodilation and contributing to these diseases. In cardiovascular disorders eNOS interacts with proteins such as the angiotensin II type 1 receptor which can negatively impact its function exacerbating disease states. Investigating eNOS and its related proteins provides insight into potential therapeutic targets for improving cardiovascular health.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
eNOS (phospho S1177) was immunoprecipitated from 0.35 mg of HUVEC (human umbilical vein endothelial cell line) treated with 10 ng/ml VEGF for 5 min, whole cell lysate with Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717 at 1/30 dilution. Western blot was performed from the immunoprecipitate using Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used for detection at 1/10000 dilution.
Lane 1: HUVEC treated with VEGF whole cell lysate 10 μg (Input).
Lane 2: Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717 IP in HUVEC treated with VEGF whole cell lysate.
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717 in HUVEC treated with VEGF whole cell lysate.
Exposure time: 30 seconds.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
The 60 kDa band may be a cleaved form of eNOS (PMID: 16195740).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717).
All lanes: Immunoprecipitation - Anti-eNOS (phospho S1177) antibody [EPR20991] (Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717)
Developed using the ECL technique.
Predicted band size: 133 kDa
Observed band size: 140 kDa
Dot blot analysis of eNOS (phospho S1177) labeled with Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717 at 1/1000 dilution.
Lane 1: eNOS (phospho S1177) peptide.
Lane 2: eNOS non-phospho peptide.
Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution was used as secondary antibody.
Exposure time: 1 minute.
Blocking/Dilution buffer: 5% NFDM/TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717).
Blocking/Dilution buffer: 5% NFDM/TBST.
The 60 kDa band may be a cleaved form of eNOS (PMID: 16195740).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717).
All lanes: Western blot - Anti-eNOS (phospho S1177) antibody [EPR20991] (Anti-eNOS (phospho S1177) antibody [EPR20991] ab215717) at 1/1000 dilution
Lane 1: Untreated HUVEC (human umbilical vein endothelial cell line) whole cell lysate at 10 µg
Lane 2: HUVEC (human umbilical vein endothelial cell line) treated with 10 ng/ml VEGF for 5 min, whole cell lysate at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 133 kDa
Observed band size: 140 kDa
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com